Biodesix, Inc. (NASDAQ:BDSX) Insider Gary Anthony Pestano Sells 16,748 Shares

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $15,408.16. Following the completion of the transaction, the insider now directly owns 156,008 shares of the company’s stock, valued at approximately $143,527.36. This represents a 9.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Biodesix Trading Down 1.1 %

NASDAQ BDSX traded down $0.01 during trading on Wednesday, reaching $0.94. 170,859 shares of the stock traded hands, compared to its average volume of 460,809. The firm has a market cap of $136.74 million, a price-to-earnings ratio of -2.41 and a beta of 1.06. The stock’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.49. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.04.

Institutional Trading of Biodesix

Institutional investors have recently made changes to their positions in the business. Barclays PLC lifted its position in shares of Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Biodesix by 17.1% during the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after buying an additional 22,500 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix during the 3rd quarter worth about $262,000. Stephens Inc. AR bought a new position in Biodesix during the fourth quarter worth about $303,000. Finally, Geode Capital Management LLC increased its position in Biodesix by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock worth $1,266,000 after acquiring an additional 22,623 shares during the period. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.